Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Testning av säkerheten för Dapagliflozin före kirurgi för behandling av patienter med stadium IA lungadenokarcinom

3 november 2026 uppdaterad av: Jonsson Comprehensive Cancer Center

En öppen etikettsstudie om säkerhet och tolerabilitet för Dapagliflozin i lungadenokarcinom i stadium IA

This early phase I trial tests the safety and side effects of dapagliflozin given prior to surgery in patients with stage IA lung adenocarcinoma. Dapagliflozin is approved by the Food and Drug Administration (FDA) for the treatment of diabetes and heart failure. It is an SGLT2 inhibitor. Stage I lung adenocarcinomas express significantly higher levels of the SGLT2 protein than other stages, and research suggests that SGLT2 inhibition improves lung cancer outcomes in patients with diabetes. In this study, dapagliflozin is being used off-label, which means it is being used for a condition that it was not originally approved for by the FDA. The investigational study drug is a neoadjuvant treatment, meaning the drug is given before surgery to try and help make the surgery more effective.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVE:

I. To assess safety and tolerability of administering 30 days of neoadjuvant dapagliflozin propanediol (dapagliflozin) before surgery in subjects with stage Ia lung adenocarcinoma.

SECONDARY OBJECTIVE:

I. To measure the effects of dapagliflozin on tumor cell proliferation in lung adenocarcinoma.

EXPLORATORY OBJECTIVES:

I. To measure the effects of neoadjuvant dapagliflozin on biological and metabolic parameters.

II. To measure the effects of neoadjuvant dapagliflozin on biomarkers.

OUTLINE:

Patients receive dapagliflozin orally (PO) once daily (QD) for 30 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT)-guided biopsy on study and collection of blood and urine samples throughout the study.

After completion of study treatment, patients are followed up between days 64 and 72.

Studietyp

Interventionell

Inskrivning (Beräknad)

48

Fas

  • Tidig fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90095
        • Rekrytering
        • UCLA / Jonsson Comprehensive Cancer Center
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Claudio Scafoglio, MD/PhD
        • Huvudutredare:
          • Jane Yanagawa, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

22 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Must be able to provide written informed consent
  • Male or female ≥ 22 years of age at visit 1
  • Histologically confirmed stage Ia lung adenocarcinoma, with availability of biopsy tissue for Ki-67 determination
  • Planning to undergo surgery for lung adenocarcinoma
  • Willing and able to receive a research CT-guided lung biopsy
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Leukocytes ≥ 3.0 K/mm^3
  • Absolute neutrophil count ≥ 1.5 K/mm^3
  • Platelets ≥ 100 K/mm^3
  • Total bilirubin ≤ 2 mg/dl
  • Aspartate aminotransferase (AST) ≤ 62 IU/L
  • Alanine aminotransferase (ALT) ≤ 70 IU/L
  • Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2
  • Diabetic status: diabetic subjects who are not currently receiving treatment will be included in the study. Diabetic subjects who are under treatment with insulin or oral anti-diabetic drugs will be enrolled under observation by endocrinologists on the team, to adjust the dose of the standard of care diabetic drugs to prevent hypoglycemia
  • Females of child-bearing potential must have a negative pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Females of childbearing potential must agree to avoid pregnancy during the study and omit to abstinence from heterosexual intercourse or agree to use two methods of birth control (one highly effective method and one additional effective method) at least 4 weeks before the start of protocol therapy
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

  • Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. Women of child-bearing age will receive a urine pregnancy test to confirm eligibility
  • Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study
  • Current or previous treatment with SGLT2 inhibitors
  • History of other malignancies with exception of malignancies for which all treatment was completed at least 2 years before registration with no evidence of disease and locally treated skin squamous or basal cell carcinoma
  • Currently receiving any other investigational agents
  • Currently receiving regularly scheduled systemic steroids in the form of prednisone or dexamethasone (more than 10 mg prednisone daily or equivalent). Topical steroid ointments or creams for occasional skin rash is allowed
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dapagliflozin
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, ketoacidosis, severe kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73m^2)
  • Subjects with HIV are eligible unless their cluster of differentiation 4 (CD4+) T-cell counts are < 350 cells/µL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective antiretroviral therapy (ART) according to Department of Health and Human Services (DHHS) treatment guidelines is recommended

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment (dapagliflozin)

Patients receive dapagliflozin PO QD for 30 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT-guided biopsy on study and collection of blood and urine samples throughout the study.

Ancillary studies

Undergo collection of blood and urine samples

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling

Undergo CT-guided biopsy

Andra namn:
  • Datortomografistyrd nålbiopsi
  • CT assisterad biopsi
  • CT guidad biopsi
  • Datortomografi biopsi

Given PO

Andra namn:
  • Farxiga
  • Dapaglifluzin Propylenglykol Hydrat
  • Dapagliflozin S-propylenglykol Monohydrat

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of adverse events
Tidsram: Up to day 64-72

Will be measured by frequency and severity of toxicities related to dapagliflozin per Common Terminology Criteria for Adverse Events version 6.0. Data will be summarized. Adverse events, severe adverse events, and adverse drug reactions will be coded by body system and Medical Dictionary for Regulatory Activities classification term. Adverse events will be tabulated and will include the number of patients for whom the event occurred, the rate of occurrence, and the severity and relationship to study drug.

Up to day 64-72

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Tumor cell proliferation change
Tidsram: From biopsy to surgery up to day 64-72

Tumor cell proliferation change will be measured by percentage of Ki-67-positive cells at 3 separate timepoints: 1. pre-treatment archival tissue of standard of care diagnostic lung biopsy samples; 2. pre-treatment research computed tomography-guided lung biopsy; 3. post-treatment archival tissue from the standard of care lung tissue sample from the surgical resection. Will utilize mixed effect negative binomial regression models to compare the Ki-67 in pre- versus post-investigational study drug treatment lung biopsy samples. The outcome in these models will be the number of Ki-67 positive cells in the lung biopsy. The primary inference for the efficacy of the treatment will be the time effect in the model which will test whether the rate of Ki-67 positivity changes is due to the treatment.

From biopsy to surgery up to day 64-72

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Claudio Scafoglio, MD/PhD, UCLA / Jonsson Comprehensive Cancer Center
  • Huvudutredare: Jane Yanagawa, MD, UCLA / Jonsson Comprehensive Cancer Center

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 december 2025

Primärt slutförande (Beräknad)

29 juni 2028

Avslutad studie (Beräknad)

29 juni 2029

Studieregistreringsdatum

Först inskickad

13 november 2025

Först inskickad som uppfyllde QC-kriterierna

17 november 2025

Första postat (Faktisk)

19 november 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera